![logo](/logos/CYP.AX.webp)
Cynata Therapeutics Limited
ASX:CYP.AX
0.2 (AUD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Cynata Therapeutics Limited |
Symbool | CYP.AX |
Munteenheid | AUD |
Prijs | 0.2 |
Beurswaarde | 36,135,200 |
Dividendpercentage | 0% |
52-weken bereik | 0.105 - 0.345 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Kilian Kelly |
Website | https://www.cynata.com |
An error occurred while fetching data.
Over Cynata Therapeutics Limited
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (AUD)
Cijfers zijn in miljoenen (AUD)